Louis Aronne has noted, while these drugs demonstrate remarkable efficacy, there remains a need for ongoing advancements in weight-loss drug development to better meet the needs of all patients
has received honoraria from Boehringer Ingelheim, Eli Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometic, Bristol Myers Squibb, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim, Eli Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo Nordisk
Added Tumor-infiltrating lymphocyte therapy as a new subsection
There is a distinct difference between feeling the medication and seeing the physical results